Eli Lilly and Company (NYSE:LLY) Shares Sold by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 915,360 shares of the company’s stock after selling 1,870 shares during the quarter. Eli Lilly and Company makes up 1.5% of DekaBank Deutsche Girozentrale’s portfolio, making the stock its 6th biggest holding. DekaBank Deutsche Girozentrale’s holdings in Eli Lilly and Company were worth $790,159,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GHP Investment Advisors Inc. increased its position in Eli Lilly and Company by 5.1% during the third quarter. GHP Investment Advisors Inc. now owns 1,848 shares of the company’s stock worth $1,638,000 after purchasing an additional 89 shares during the last quarter. Covenant Partners LLC increased its position in Eli Lilly and Company by 436.6% during the third quarter. Covenant Partners LLC now owns 5,371 shares of the company’s stock worth $4,758,000 after purchasing an additional 4,370 shares during the last quarter. PFG Investments LLC boosted its stake in Eli Lilly and Company by 10.6% during the third quarter. PFG Investments LLC now owns 7,572 shares of the company’s stock worth $6,709,000 after buying an additional 723 shares during the period. Pathway Financial Advisers LLC boosted its stake in Eli Lilly and Company by 92,759.9% during the third quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company’s stock worth $905,774,000 after buying an additional 1,021,287 shares during the period. Finally, Masso Torrence Wealth Management Inc. boosted its stake in Eli Lilly and Company by 12.5% during the third quarter. Masso Torrence Wealth Management Inc. now owns 703 shares of the company’s stock worth $623,000 after buying an additional 78 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.2 %

Shares of Eli Lilly and Company stock opened at $892.70 on Monday. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The company has a 50 day moving average of $919.74 and a 200 day moving average of $863.20. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The company has a market capitalization of $848.43 billion, a P/E ratio of 131.47, a P/E/G ratio of 3.24 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, research analysts forecast that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on LLY. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price for the company. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,013.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.